← Leaderboards
Frank R. Jones
Etubics Corporation
$11,439,876
Attributed
$13,670,224
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2008–18$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$13,670,224 · 10
By mechanism
R44$6,957,930 · 3
R01$4,460,696 · 1
N44$1,499,001 · 1
R43$602,621 · 4
N43$149,976 · 1
Top collaborators
- Slobodan Paessler5 shared
Others in their field
Top investigators on “Adenoviruses”
- David Heimbrook · Leidos Biomedical Research, Inc.$87,846,116
- Jaap Goudsmit · Beth Israel Deaconess Medical Center$53,211,886
- Larry Arthur$34,591,506
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,036,726
- William George Nelson · Johns Hopkins University$30,145,983
- Daniel F. Hoft · Saint Louis University$29,294,132
Research focus
AdenovirusesImmunizationImmuneBaseVaccinesImmunityVectorAnimalsProteinsImmune ResponseNovel VaccinesAntigensResponseImmunogenicityTumorClinical TrialsGenesGenerationsRegimenDna-Directed Dna PolymeraseSerotypingDoseIn VivoVector Vaccine
Grant awards (19)
Development of a Universal Influenza Vaccine$734,209
R01 · FY2018 · AI · contact PI
Development of a Universal Influenza Vaccine$612,096
R01 · FY2017 · AI · contact PI
Development of a Universal Influenza Vaccine$594,261
R01 · FY2016 · AI · contact PI
Development of a Universal Influenza Vaccine$1,121,460
R01 · FY2015 · AI · contact PI
Development of a Universal Influenza Vaccine$1,398,670
R01 · FY2014 · AI · contact PI
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci$414,421
R44 · FY2014 · DE · contact PI
Development of an Ad5-CEA/Brachyury Vector Approach for Cancer Treatment$202,654
R43 · FY2014 · CA · contact PI
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci$99,687
R44 · FY2014 · DE · contact PI
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci$619,720
R44 · FY2013 · DE · contact PI
TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING A$1,499,001
N44 · FY2011 · CA · contact PI
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee$1,133,414
R44 · FY2011 · AI · contact PI
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci$163,405
R43 · FY2011 · DE · contact PI
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee$1,149,641
R44 · FY2010 · AI · contact PI
Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment$982,054
R44 · FY2010 · CA · contact PI
Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment$1,488,231
R44 · FY2009 · CA · contact PI
Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee$1,070,762
R44 · FY2009 · AI · contact PI
SBIR TOPIC 255 DEVELOPMENT OF ANTICANCER AGENTS$149,976
N43 · FY2009 · CA · contact PI
Development of a Novel Her2/neu Expressing Adenovirus for Treatment$123,567
R43 · FY2009 · CA · contact PI
Development of a Novel CEA Expressing Adenovirus for Treatment$112,995
R43 · FY2008 · CA · contact PI